Psychopharmacology
-
Clinical Trial
Psilocybin with psychological support for treatment-resistant depression: six-month follow-up.
Recent clinical trials are reporting marked improvements in mental health outcomes with psychedelic drug-assisted psychotherapy. ⋯ Although limited conclusions can be drawn about treatment efficacy from open-label trials, tolerability was good, effect sizes large and symptom improvements appeared rapidly after just two psilocybin treatment sessions and remained significant 6 months post-treatment in a treatment-resistant cohort. Psilocybin represents a promising paradigm for unresponsive depression that warrants further research in double-blind randomised control trials.